Vertex Pharmaceuticals
VRTX
#185
Rank
C$157.39 B
Marketcap
C$613.89
Share price
0.56%
Change (1 day)
2.77%
Change (1 year)

P/E ratio for Vertex Pharmaceuticals (VRTX)

P/E ratio as of January 2026 (TTM): 30.9

According to Vertex Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 30.9449. At the end of 2024 the company had a P/E ratio of -195.

P/E ratio history for Vertex Pharmaceuticals from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-195-774.54%
202329.030.26%
202222.2-7.81%
202124.16.4%
202022.7-52.66%
201947.9138.24%
201820.1-85.64%
2017140-189.35%
2016-157187.75%
2015-54.543.97%
2014-37.83.88%
2013-36.4-57.41%
2012-85.5

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Gilead Sciences
GILD
19.0-38.58%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
158 411.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
14.4-53.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
18.6-39.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
20.9-32.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Enanta Pharmaceuticals
ENTA
-3.30-110.66%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.